Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Market Cap	$258.71M	P/E Ratio	N/A
52W High	$6.45	52W Low	$2.46
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-49.9%	52W Position	87.4%
Overall Score	52	Value Score	60
Quality Score	--	Technical Score	45

EPS Current Est	$-2.09	EPS Next Est	$-1.53
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVIR	$5.95	-0.42%	273.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVIR	$5.95	-0.4%	273.58K
3
4
5
6

AVIR

AVIR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Atea Pharmaceuticals Inc. Data in Excel

Get Atea Pharmaceuticals Inc. Data in Excel